Novo Nordisk
Develops treatments for serious chronic diseases like diabetes, obesity, and hemophilia.
NOVO | CO
Overview
Corporate Details
- ISIN(s):
- DK0062498333 (+1 more)
- LEI:
- 549300DAQ1CVT6CXN342
- Country:
- Denmark
- Address:
- Novo Alle 1, 2880 Bagsværd
- Website:
- https://www.novonordisk.com/
- Sector:
- Manufacturing
Description
Novo Nordisk is a global healthcare company dedicated to developing treatments for serious chronic diseases. With over a century of innovation, it is a world leader in diabetes care, providing a comprehensive portfolio of insulin products and GLP-1 receptor agonists. Leveraging its expertise in metabolic conditions, the company has also become a prominent force in obesity management. Novo Nordisk's therapeutic focus extends to other serious chronic conditions, including rare bleeding disorders like hemophilia and growth hormone-related disorders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-01 13:13 |
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both …
|
Danish | HTML • 10.0 KB | ||
| 2024-10-28 13:50 |
FORM 6-K
|
English | ZIP • 212.2 KB | ||
| 2024-10-28 13:11 | English | PDF • 116.7 KB | |||
| 2024-10-28 13:11 |
Novo Nordisk A/S - share repurchase programme
|
Danish | PDF • 143.6 KB | ||
| 2024-10-28 13:11 |
Novo Nordisk A/S - share repurchase programme
|
Danish | HTML • 11.0 KB | ||
| 2024-10-21 16:34 |
FORM 6-K
|
English | ZIP • 212.0 KB | ||
| 2024-10-21 14:50 | English | PDF • 117.1 KB | |||
| 2024-10-21 14:50 |
Novo Nordisk A/S - share repurchase programme
|
Danish | PDF • 1.3 MB | ||
| 2024-10-21 14:50 |
Novo Nordisk A/S - share repurchase programme
|
Danish | HTML • 10.0 KB | ||
| 2024-10-21 14:31 |
FORM 6-K
|
English | ZIP • 212.6 KB | ||
| 2024-10-21 11:26 | English | PDF • 152.4 KB | |||
| 2024-10-21 11:26 |
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of majo…
|
Danish | HTML • 8.4 KB | ||
| 2024-10-15 12:05 |
FORM 6-K
|
English | ZIP • 212.0 KB | ||
| 2024-10-14 14:06 | English | PDF • 1.6 MB | |||
| 2024-10-14 14:06 |
Novo Nordisk A/S - share repurchase programme
|
Danish | PDF • 104.0 KB |
Automate Your Workflow. Get a real-time feed of all Novo Nordisk filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Novo Nordisk
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Novo Nordisk via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
